The loan carries an interest rate set at the prime rate plus 4.25%, with a minimum interest rate of 10.75%. Borrowings will be subject to an interest-only payment period lasting 48 months, after which the principal will be repayable in equal monthly installments. This structure provides Hyperfine with a manageable repayment schedule, allowing the company to focus on growth and operational execution during the initial years of the loan.
In conjunction with the loan, Hyperfine issued warrants to purchase up to 1,083,335 shares of its Class A common stock at an exercise price of $1.20 per share. These warrants are designed to incentivize the lender while providing Hyperfine with additional capital flexibility. The company is also obligated to file a registration statement with the SEC to facilitate the resale of the shares underlying the warrants, ensuring liquidity for the lender.
The Loan Agreement includes customary covenants and events of default, which are standard in such financing arrangements. These provisions are intended to protect the lender's interests while also providing Hyperfine with the necessary capital to enhance its operational capabilities. The company’s obligations under the agreement are guaranteed by its wholly-owned subsidiaries, further securing the lender's position.
Overall, this financing arrangement is a strategic move for Hyperfine, providing essential capital to support its growth initiatives while maintaining a structured repayment plan. The terms of the loan and the associated warrants are expected to have a positive impact on the company's liquidity and operational execution, positioning it for future success in the competitive healthcare technology market.
